A randomized controlled trial of vitamin D dosing strategies after acute hip fracture: No advantage of loading doses over daily supplementation

Table 2 Mean (95% CI) 25-OHD and percent reaching 75 nmol/L (N = 65)

	Placebo	50,000	100,000	p-value
Baseline (n = 59)
Mean 25-OHD, unadjusted
serum collection at -3 to 0 days, n = 34	58.7 (43.4-74.0) n = 7	52.3 (37.4-67.2) n = 14	44.3 (30.8-57.8) n = 13	0.39
serum collection at days 1-3, n = 25	41.6 (29.3-53.9) n = 11	59.0 (28.4-89.6) n = 6	76.0 (49.1-102.8) n = 8	0.03^†
Mean 25-OHD, adjusted for time to measure, n = 59^‡	46.7 (34.8-58.6) n = 18)	53.5 (42.3-64.8) n = 20	58.4 (47.3-69.5) n = 21	0.37
4-week (n = 50)
Mean 25-OHD, unadjusted	69.8 (59.8-79.8) n = 17	84.1 (69.3-98.9) n = 17	75.6 (67.6-83.6) n = 16	0.17
Mean 25-OHD, adjusted for time to measure*	69.3 (58.4-80.2) n = 17	84.5 (73.7-95.3) n = 17	75.6 (64.5-86.8) n = 16	0.15
Proportion ≥ 75 nmol/L	47.1%	58.8%	50.0%	0.76
3-month (n = 47)
Unadjusted	85.0 (73.6-93.3) n = 17	85.2 (74.5-95.9) n = 12	74.3 (66.1-82.5) n = 18	0.17
Mean 25-OHD, adjusted for time to measure**	86.7 (77.6-95.9) n = 17	84.2 (73.6-94.9) n = 12	73.3 (64.5-82.1) n = 18	0.09
Proportion ≥ 75 nmol/L	76.5%	75%	44.4%	0.09

Baseline data (n = 59) was missing for two participants, and four outliers with 25-OHD taken at 6, 10 or 12 days were not included. 4-week data (n = 50) was missing for 13 participants, and two outliers with 25-OHD taken at <13 days were not included. 3-month data (n = 47) was missing for 18 participants. ^†Significant difference between 100,000 and placebo (post-hoc). ^‡Mean time between bolus vitamin D dose and baseline 25-OHD measure was 0.36 days. *Mean time between bolus vitamin D dose and 25-OHD at second measure was 28.1 days. **Mean time between bolus vitamin D dose and 25-OHD at third measure was 98.9 days.

ISSN: 1471-2474